Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does RITUXIMAB-PVVR Cause Intentional product use issue? 627 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 627 reports of Intentional product use issue have been filed in association with RITUXIMAB-PVVR. This represents 14.9% of all adverse event reports for RITUXIMAB-PVVR.

627
Reports of Intentional product use issue with RITUXIMAB-PVVR
14.9%
of all RITUXIMAB-PVVR reports
56
Deaths
146
Hospitalizations

How Dangerous Is Intentional product use issue From RITUXIMAB-PVVR?

Of the 627 reports, 56 (8.9%) resulted in death, 146 (23.3%) required hospitalization, and 18 (2.9%) were considered life-threatening.

Is Intentional product use issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for RITUXIMAB-PVVR. However, 627 reports have been filed with the FAERS database.

What Other Side Effects Does RITUXIMAB-PVVR Cause?

Off label use (2,079) Condition aggravated (514) Death (338) Covid-19 (322) Fatigue (318) Dyspnoea (314) Inappropriate schedule of product administration (311) Headache (291) Pruritus (288) Nausea (286)

What Other Drugs Cause Intentional product use issue?

INFLIXIMAB (11,028) RITUXIMAB (9,602) INFLIXIMAB-DYYB (7,549) TOCILIZUMAB (5,078) METHOTREXATE (4,087) PREDNISONE (3,961) ABATACEPT (3,693) ADALIMUMAB (3,557) NIVOLUMAB (3,297) LEFLUNOMIDE (3,280)

Which RITUXIMAB-PVVR Alternatives Have Lower Intentional product use issue Risk?

RITUXIMAB-PVVR vs RIVAROXABAN RITUXIMAB-PVVR vs RIVASTIGMINE RITUXIMAB-PVVR vs RIVOTRIL RITUXIMAB-PVVR vs RIZATRIPTAN RITUXIMAB-PVVR vs ROACTEMRA

Related Pages

RITUXIMAB-PVVR Full Profile All Intentional product use issue Reports All Drugs Causing Intentional product use issue RITUXIMAB-PVVR Demographics